<DOC>
	<DOCNO>NCT00253500</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , epirubicin , work different way stop growth tumor cell , either kill cell stop divide . Giving epirubicin surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study well epirubicin work treat woman undergo surgery stage I , stage II , stage III breast cancer .</brief_summary>
	<brief_title>Epirubicin Treating Women Who Are Undergoing Surgery Stage I , Stage II , Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete pathological clinical response rate woman undergo surgery resectable stage I-III breast cancer treat neoadjuvant dose-intensified epirubicin hydrochloride . Secondary - Determine toxicity regimen patient . - Determine predictive value HER2 gene amplification topoisomerase II-alpha gene amplification deletion disease progression pathological clinical complete response patient treat regimen . - Correlate gene expression profile pathologic complete response , clinical complete response , less complete response , disease progression patient treat regimen . OUTLINE : Patients receive epirubicin hydrochloride IV day 1 pegfilgrastim subcutaneously day 2 . Treatment repeat every 14 day 4 course absence disease progression unacceptable toxicity . Four week later , patient undergo partial mastectomy simple mastectomy plus axillary staging procedure . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer Stage I , II , III disease ( T1 , T2 , T4 ; N02 ; M0 ) Resectable disease Unidimensionally measurable disease Primary tumor ≥ 2 cm No known distant metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Sex Female Menopausal status Not specify Performance status ECOG 02 Life expectancy Not specify Hematopoietic WBC ≥ 3,500/mm^3 Hemoglobin ≥ 8 g/dL Platelet count ≥ 100,000/mm^3 No know untreated bleeding diathesis Hepatic AST ≤ 2 time upper limit normal Bilirubin ≤ 1.5 mg/dL Renal Creatinine ≤ 1.5 mg/dL OR Creatinine clearance ≥ 60 mL/min Cardiovascular LVEF ≥ 50 % echocardiogram , MUGA , cardiac catheterization Other Not pregnant breastfeed Fertile patient must use effective contraception Negative pregnancy test No concurrent illness would preclude study treatment No known hypersensitivity Escherichia coliderived protein , pegfilgrastim , filgrastim ( GCSF ) , component product PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>